Ibrahim Turkoz

Ibrahim Turkoz

Auto-generated profile, based on publicly available information

Ibrahim Turkoz

Janssen Research & Development, LLC, Titusville, NJ, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2020 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
PDF file
ITIbrahim Turkoz
Ibrahim Turkoz
LALarry Alphs
Larry Alphs
JSJaskaran Singh
Jaskaran Singh
CJCarol Jamieson
Carol Jamieson
EDElla Daly
Ella Daly
ARA. John Rush
A. John Rush
Objective: To use the Clinical Global Impression‐Severity (CGI‐S) scale to estimate clinically meaningful and clinically substantial changes as measured using the Montgomery‐Åsberg Depression Rating Scale (MADRS), the Sheehan Disability Scale (SDS), and the Patient Health Questionnaire‐9 (PHQ‐9) in patients with treatment‐resistant depression (TRD).Methods: Pooled data were derived from two 4‐week, randomized, active‐controlled studies evaluating esketamine nasal spray (ESK) plus oral antidepressant (OAD) or OAD plus placebo nasal spray (PBO) in adults with TRD (N = 565). CGI‐S, MADRS, SDS, and PHQ‐9 scores were obtained at baseline and over 4 weeks of treatment. In this post hoc analysis, change scores on the MADRS, SDS, and PHQ‐9 that corresponded to a clinically meaningful (1‐point) or clinically substantial (2‐point) change on the CGI‐S scale were identified.Results: Clinically meaningful changes in CGI‐S scores after 28 days corresponded to 6‐, 4‐, and 3‐point changes from baseline on the MADRS, SDS, and PHQ‐9, respectively. Similarly, a 2‐point CGI‐S score change (clinically substantial change) corresponded to a 12‐, 8‐, and 6‐point change on the MADRS, SDS, and PHQ‐9, respectively. The proportion of patients showing substantial clinical improvement in the ESK plus OAD group versus the OAD plus PBO group after 28 days of treatment favored ESK plus OAD: 69.0% vs 55.3% (MADRS), 64.5% vs 48.9% (SDS), and 77.1% vs 64.7% (PHQ‐9).Conclusion: We provide a basis for identifying clinically meaningful and clinically substantial changes as assessed with commonly used outcome measures for depression to facilitate the translation of clinical trial results into clinical practice.

1 July 2008 in International Clinical Psychopharmacology
Verified
Journal Article
Closed access
CCCarla M. Canuso
Carla M. Canuso
EYEriene A. Youssef
Eriene A. Youssef
CBCynthia A. Bossie
Cynthia A. Bossie
ITIbrahim Turkoz
Ibrahim Turkoz
ASAndreas Schreiner
Andreas Schreiner
GSGeorge M. Simpson
George M. Simpson
To assess the effect of paliperidone extended-release (ER) tablets in patients with acute symptoms who had previously received risperidone. Data for this post-hoc analysis were pooled from three 6-week, double-blind, placebo-controlled trials in patients treated with paliperidone ER 3-12 mg/day or placebo. Patients had to have received risperidone for > or =4 weeks within 2 weeks of study entry. Assessments were done using the Positive and Negative Syndrome Scale, Clinical Global Impressions-Severity scale, Personal and Social Performance scale, the Simpson-Angus Scale , and adverse event (AE) reports. Altogether, 198 patients (paliperidone ER, n=142; placebo, n=56) met the established criteria. Mean (SD) duration of prior risperidone treatment and dose were 418.8 (572.8) days and 4.4 (2.5) mg/day for paliperidone ER and 527.0 (805.3) days and 4.1 (2.5) mg/day for placebo. Study completion rates were 61.3% for paliperidone ER versus 42.9% for placebo. At endpoint, paliperidone ER showed significant improvement versus placebo (P or =10% with paliperidone ER versus placebo were headache (16.2 vs. 16.1%), insomnia (14.1 vs. 16.1%), and agitation (8.5 vs. 10.7%). AE-related discontinuations were 2.1% with paliperidone ER and 5.4% with placebo. In patients who had received risperidone previously but remained sufficiently symptomatic for enrollment, paliperidone ER was significantly more effective than placebo in reducing symptoms and producing functional gains.

7 February 2011 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
ITIbrahim Turkoz
Ibrahim Turkoz
CBCynthia A Bossie
Cynthia A Bossie
JLJean-Pierre Lindenmayer
Jean-Pierre Lindenmayer
NSNina Schooler
Nina Schooler
CCCarla M Canuso
Carla M Canuso
To compare the efficacy and tolerability of paliperidone extended-release (ER) with risperidone immediate-release using propensity score methodology. Six double-blind, randomized, placebo-controlled, short-term clinical trials for acute schizophrenia with availability of individual patient-level data were identified (3 per compound). Propensity score pairwise matching was used to balance observed covariates between the paliperidone ER and risperidone patient populations. Scores were generated using logistic regression models, with age, body mass index, race, sex, baseline Positive and Negative Syndrome Scale (PANSS) total score and baseline Clinical Global Impressions–Severity (CGI-S) score as factors. The dosage range of paliperidone ER (6-12 mg/day) was compared with 2 risperidone dosage ranges: 2-4 and 4-6 mg/day. The primary efficacy measure was change in PANSS total score at week 6 end point. Tolerability end points included adverse event (AE) reports and weight. AEs with rates ≥5% and with a ≥2% difference between paliperidone ER and risperidone were identified. Completion rates for placebo-treated subjects in paliperidone ER trials (n = 95) and risperidone trials (n = 122) groups were 36.8% and 51.6%, respectively; end point changes on PANSS total scores were similar (p = 0.768). Completion rates for subjects receiving paliperidone ER 6-12 mg/day (n = 179), risperidone 2-4 mg/day (n = 113) or risperidone 4-6 mg/day (n = 129) were 64.8%, 54.0% and 66.7%, respectively (placebo-adjusted rates: paliperidone ER vs risperidone 2-4 mg/day, p = 0.005; paliperidone ER vs risperidone 4-6 mg/day, p = 0.159). PANSS total score improvement with paliperidone ER was greater than with risperidone 2-4 mg/day (difference in mean change score, -6.7; p < 0.05) and similar to risperidone 4-6 mg/day (0.2; p = 0.927). Placebo-adjusted AEs more common with paliperidone ER were insomnia, sinus tachycardia and tachycardia; more common with risperidone were somnolence, restlessness, nausea, anxiety, salivary hypersecretion, akathisia, dizziness and nasal congestion. Weight changes with paliperidone ER and risperidone were similar (paliperidone ER vs risperidone 2-4 mg/day, p = 0.489; paliperidone ER vs risperidone 4-6 mg/day, p = 0.236). This indirect database analysis suggested that paliperidone ER 6-12 mg/day may be more efficacious than risperidone 2-4 mg/day and as efficacious as risperidone 4-6 mg/day. The AE-adjusted incidence rates suggest differences between treatments that may be relevant for individual patients. Additional randomized, direct, head-to-head clinical trials are needed to confirm these findings.

1 January 2013 in Annals of General Psychiatry
Verified
Journal Article
Open access
PDF file
MMMichael Markowitz
Michael Markowitz
DFDong-Jing Fu
Dong-Jing Fu
BLBennett Levitan
Bennett Levitan
SGSrihari Gopal
Srihari Gopal
ITIbrahim Turkoz
Ibrahim Turkoz
LALarry Alphs
Larry Alphs
Increasing availability and use of long-acting injectable antipsychotics have generated a need to compare these formulations with their oral equivalents; however, a paucity of relevant data is available.

1 August 2013 in Journal of Affective Disorders
Verified
Journal Article
Closed access
ITIbrahim Turkoz
Ibrahim Turkoz
DFDong-Jing Fu
Dong-Jing Fu
CBCynthia A. Bossie
Cynthia A. Bossie
JSJohn J. Sheehan
John J. Sheehan
LALarry Alphs
Larry Alphs

20 July 2021 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
PDF file
ITIbrahim Turkoz
Ibrahim Turkoz
EDElla Daly
Ella Daly
JSJaskaran Singh
Jaskaran Singh
XLXiwu Lin
Xiwu Lin
YTYevgen Tymofyeyev
Yevgen Tymofyeyev
JNJ. Craig Nelson
J. Craig Nelson
Only some patients with treatment-resistant depression who ultimately respond to esketamine plus an oral antidepressant do so within the first 2 doses. This study estimated the likelihood of ultimate response in patients not responding in the first week.